Vaginal DHEA After Cancer: What the Moisturizer Comparison Found

Vaginal DHEA is a hormone treatment. Prasterone, another name for DHEA, is the steroid in the US prescription insert Intrarosa. Estrogen is one of its metabolites. The approved indication is moderate to severe painful sex associated with menopausal vulvar and vaginal atrophy.¹

The Alliance trial N10C1 measured vaginal symptoms over 12 weeks. Its registry clarifies who entered the comparison.²

There were 464 entrants, but 443 randomized participants

The abstract describes 464 women randomized. The registry says 464 entered, but 19 withdrew consent and two could not classify their main symptom before randomization. Its treatment groups contained 147 women receiving 3.25 mg DHEA, 149 receiving 6.5 mg and 147 receiving comparison gel, totaling 443.²³

Eligible women were postmenopausal cancer survivors with no current evidence of disease and at least moderate dryness or painful sex. Tamoxifen or aromatase inhibitors were allowed. Prior pelvic radiation and certain anatomical changes after pelvic surgery were excluded, limiting application to those situations.²

Every group received a moisturizing gel

All groups used compounded moisturizing gel nightly, with or without DHEA. Participants and investigators were blinded. The marketed solid insert was not tested.³

Women rated their worst symptom on a five-point scale. The primary analysis required treatment and a week-12 evaluation, which not all participants provided.²

Symptom scores fell 1.5 points with moisturizer, 1.6 with 3.25 mg DHEA and 1.8 with 6.5 mg. Neither dose significantly outperformed moisturizer at week 12, despite an earlier week-eight difference favoring 6.5 mg.³

Sexual function and blood hormones answered different questions

The 6.5 mg group improved more on the secondary Female Sexual Function Index. That does not overturn the primary result. National Cancer Institute and Breast Cancer Research Foundation funding supported the study.³

A secondary analysis of the same trial, not another independent experiment, evaluated blood samples from 345 women. Vaginal DHEA increased circulating DHEA-S and testosterone. Estradiol increased significantly with 6.5 mg, but not with 3.25 mg, compared with moisturizer; no significant estradiol increase was found among aromatase-inhibitor users.⁴

Only 46 women contributed evaluable vaginal-cell and pH measurements. The authors reported favorable tissue changes and hormone concentrations within low postmenopausal ranges. Those laboratory findings do not establish that cancer recurrence risk is unchanged over years.⁴

A later insert trial stopped after enrolling eight women

The registry for NCT04493333 reports five women assigned to Intrarosa and three to Replens, with results posted in 2024. It stopped because of low recruitment. Only two Intrarosa participants and no comparison participants completed the study. That leaves no useful completed-group comparison, despite this trial testing the marketed insert in aromatase-inhibitor users.⁵

Current US guidance leaves a decision to discuss

The 2025 AUA/SUFU/AUGS guideline’s breast-cancer statement is labeled Expert Opinion. Its discussion acknowledges limited DHEA data in survivors and allows consideration through a decision involving the patient and multiple treating specialties. This is guidance under uncertainty, rather than a long-term randomized safety finding.⁶

The Dana-Farber Breast Oncology Center⁷ document dated April 2026 takes a more cautious position: it finds insufficient safety evidence to recommend DHEA, topical testosterone or ospemifene after breast cancer. It starts with nonhormonal moisturizers and lubricants. Its consensus originated at a 2023 center meeting; the document date does not make it a new trial.⁷

The current Intrarosa label retains a warning about current or past breast cancer and states that the product has not been studied in women with that history. That wording does not mean no DHEA research has ever included survivors. The label also contraindicates undiagnosed abnormal genital bleeding. These studies do not remove those prescribing cautions.¹

Take the product name and symptom record to the visit

The “What the Prescription Options Are” section of Down There, Decoded discusses DHEA and the added treatment discussion after breast cancer. Record whether your difficulty is daily dryness, pain at penetration or both, and which moisturizers you have tried, including frequency and irritation.

Ask your gynecologist and oncology team to explain the proposed formulation, your cancer treatment’s relevance and the review plan. Bring the actual product name: a compounded gel, a prescription insert and an oral supplement are different proposals. Our prasterone prescribing guide covers the insert’s symptom indication and precautions.